EXCLUSIVE: Anixa Biosciences Tells Benzinga Co. Announces FDA Approval Of Individual Patient IND For Its Ovarian Cancer CAR-T Therapy
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences has announced FDA approval of an Individual Patient IND for its ovarian cancer CAR-T therapy.
July 23, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences received FDA approval for an Individual Patient IND for its ovarian cancer CAR-T therapy, which could positively impact the company's stock price.
FDA approval for an Individual Patient IND is a significant milestone for Anixa Biosciences, indicating progress in their ovarian cancer CAR-T therapy. This regulatory approval is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100